In their study, in comparison to the placebo, empagliflozin increased urinary glucose excretion, improved A1C, and reduced weight with lower insulin doses over a 28-day period.14 Hypoglycemia increased the risk of morbidity and mortality in patients with T1D and has adverse effects on the patients’ quality of life. The gene discussed is INS; the disease is type 1 diabetes mellitus.